<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">35015448</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK576423</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-139274">Viloxazine</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Blesson M.</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Saint Georges University</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hiep</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Vietnam School of Medicine</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Viloxazine was marketed as an antidepressant as an immediate-release formulation in Europe for over two decades before being proposed as a potential treatment for patients with ADHD (attention deficit hyperactivity disorder). In 1971, viloxazine was first endorsed in the United Kingdom before being recognized by numerous other nations as an antidepressant. In April of 2021, the United States Food and Drug Administration (FDA) approved the use of viloxazine in children and adolescents with ADHD, specifically viloxazine extended-release capsules. This activity summarizes the indications, administration, doses, contraindications, activity, adverse events, and other critical elements of viloxazine therapy in the clinical setting related to the crucial points required by members of an interprofessional team managing the care of patients with ADHD.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s2">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s3">Mechanism of Action</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s4">Administration</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s5">Adverse Effects</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s6">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s7">Monitoring</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s8">Toxicity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s9">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s10">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s11">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>7</Day></ContributionDate><ReferenceList><Reference><Citation>Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021 Jun;35(6):643-653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219567</ArticleId><ArticleId IdType="pubmed">34003459</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe R, Leigh T, Rao BS, Todd AH. Optical isomers of 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine (viloxazine) and related compounds. J Med Chem. 1976 Aug;19(8):1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">966254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Hull JT, Liranso T, Busse GD, Melyan Z, Childress AC, A Lopez F, Rubin J. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials. Neuropsychiatr Dis Treat. 2021;17:1751-1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184252</ArticleId><ArticleId IdType="pubmed">34113106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020;12:285-300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473988</ArticleId><ArticleId IdType="pubmed">32943948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976 Aug;54(4):494-509.</Citation><ArticleIdList><ArticleId IdType="pubmed">974878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafeez S, Saquib J, Qureshi NE. Viloxazine: A new miracle drug for attention deficit hyperactivity disorder (ADHD) or just another non-stimulant? Asian J Psychiatr. 2022 Jan;67:102948.</Citation><ArticleIdList><ArticleId IdType="pubmed">34871970</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978 Jun;17(6):421-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">673157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. Viloxazine: Pediatric First Approval. Paediatr Drugs. 2021 Jul;23(4):403-409.</Citation><ArticleIdList><ArticleId IdType="pubmed">34036533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Cutler AJ, Jones NJ, Findling RL, Schwabe S. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clin Ther. 2020 Aug;42(8):1452-1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">32723670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista AP, Elliott KE. Acute ethanol intoxication regulates f-met-leu-phe-induced chemotaxis and superoxide release by neutrophils and Kupffer cells through modulation of the formyl peptide receptor in the rat. Life Sci. 1994;54(11):721-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8107522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedman G. Double-blind trial of sustained-release amitriptyline compared with viloxazine in moderate to severe depressive illness. Curr Med Res Opin. 1977;5(3):217-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">162657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Kosheleff AR, Adeojo LW, Odebo O, Adewole T, Qin P, Maletic V, Schwabe S, Nasser A. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1365-1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597116</ArticleId><ArticleId IdType="pubmed">33943033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani F, Fazio A, Artesi C, Russo M, Trio R, Oteri G, Perucca E, Di Perri R. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. J Neurol Neurosurg Psychiatry. 1992 Feb;55(2):126-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC488975</ArticleId><ArticleId IdType="pubmed">1538217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebjanic V, Grombein S. Viloxazine (Vivalan ICI) in depression: results of a field trial of 276 patients in neuropsychiatric practice. Adv Biochem Psychopharmacol. 1982;32:113-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7046360</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosnan RD, Busby AM, Holland RP. Cases of overdosage with viloxazine hydrochloride (Vivalan). J Int Med Res. 1976;4(2):83-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1026544</ArticleId></ArticleIdList></Reference><Reference><Citation>De León O, Kravcio JT, Sánchez C. [Double-blind trial of 2 antidepressive drugs]. Acta Psiquiatr Psicol Am Lat. 1977 Sep;23(3):215-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">341650</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcy M, Riboulet-Delmas G, Efthymiou ML. [Acute poisoning by viloxazine chlorhydrate taken by itself]. Encephale. 1983;9(2):137-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6641615</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35015448</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">35015448</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK576423</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-139274">Viloxazine</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Blesson M.</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Saint Georges University</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hiep</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Vietnam School of Medicine</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Viloxazine was marketed as an antidepressant as an immediate-release formulation in Europe for over two decades before being proposed as a potential treatment for patients with ADHD (attention deficit hyperactivity disorder). In 1971, viloxazine was first endorsed in the United Kingdom before being recognized by numerous other nations as an antidepressant. In April of 2021, the United States Food and Drug Administration (FDA) approved the use of viloxazine in children and adolescents with ADHD, specifically viloxazine extended-release capsules. This activity summarizes the indications, administration, doses, contraindications, activity, adverse events, and other critical elements of viloxazine therapy in the clinical setting related to the crucial points required by members of an interprofessional team managing the care of patients with ADHD.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s2">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s3">Mechanism of Action</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s4">Administration</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s5">Adverse Effects</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s6">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s7">Monitoring</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s8">Toxicity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s9">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s10">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-139274" sec="article-139274.s11">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>7</Day></ContributionDate><ReferenceList><Reference><Citation>Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021 Jun;35(6):643-653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219567</ArticleId><ArticleId IdType="pubmed">34003459</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe R, Leigh T, Rao BS, Todd AH. Optical isomers of 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine (viloxazine) and related compounds. J Med Chem. 1976 Aug;19(8):1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">966254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Hull JT, Liranso T, Busse GD, Melyan Z, Childress AC, A Lopez F, Rubin J. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials. Neuropsychiatr Dis Treat. 2021;17:1751-1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184252</ArticleId><ArticleId IdType="pubmed">34113106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020;12:285-300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473988</ArticleId><ArticleId IdType="pubmed">32943948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976 Aug;54(4):494-509.</Citation><ArticleIdList><ArticleId IdType="pubmed">974878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafeez S, Saquib J, Qureshi NE. Viloxazine: A new miracle drug for attention deficit hyperactivity disorder (ADHD) or just another non-stimulant? Asian J Psychiatr. 2022 Jan;67:102948.</Citation><ArticleIdList><ArticleId IdType="pubmed">34871970</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978 Jun;17(6):421-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">673157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. Viloxazine: Pediatric First Approval. Paediatr Drugs. 2021 Jul;23(4):403-409.</Citation><ArticleIdList><ArticleId IdType="pubmed">34036533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Cutler AJ, Jones NJ, Findling RL, Schwabe S. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clin Ther. 2020 Aug;42(8):1452-1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">32723670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista AP, Elliott KE. Acute ethanol intoxication regulates f-met-leu-phe-induced chemotaxis and superoxide release by neutrophils and Kupffer cells through modulation of the formyl peptide receptor in the rat. Life Sci. 1994;54(11):721-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8107522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedman G. Double-blind trial of sustained-release amitriptyline compared with viloxazine in moderate to severe depressive illness. Curr Med Res Opin. 1977;5(3):217-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">162657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Kosheleff AR, Adeojo LW, Odebo O, Adewole T, Qin P, Maletic V, Schwabe S, Nasser A. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1365-1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597116</ArticleId><ArticleId IdType="pubmed">33943033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani F, Fazio A, Artesi C, Russo M, Trio R, Oteri G, Perucca E, Di Perri R. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. J Neurol Neurosurg Psychiatry. 1992 Feb;55(2):126-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC488975</ArticleId><ArticleId IdType="pubmed">1538217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebjanic V, Grombein S. Viloxazine (Vivalan ICI) in depression: results of a field trial of 276 patients in neuropsychiatric practice. Adv Biochem Psychopharmacol. 1982;32:113-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7046360</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosnan RD, Busby AM, Holland RP. Cases of overdosage with viloxazine hydrochloride (Vivalan). J Int Med Res. 1976;4(2):83-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1026544</ArticleId></ArticleIdList></Reference><Reference><Citation>De León O, Kravcio JT, Sánchez C. [Double-blind trial of 2 antidepressive drugs]. Acta Psiquiatr Psicol Am Lat. 1977 Sep;23(3):215-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">341650</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcy M, Riboulet-Delmas G, Efthymiou ML. [Acute poisoning by viloxazine chlorhydrate taken by itself]. Encephale. 1983;9(2):137-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6641615</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35015448</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
